Abstract 15881: GlycA Predicts Vascular Inflammation by 18-FDG PET/CT Beyond hsCRP in Psoriasis at Baseline and 1-year Follow-up
Introduction: Recent studies suggest that hsCRP may not accurately capture CV risk in patients with inflammatory disorders such as psoriasis (PSO). GlycA, a novel inflammatory biomarker, predicted future CV events in large population based studies. Whether GlycA associates with subclinical CVD and how it performs in CVD assessment beyond hsCRP in PSO is unknown.
Hypothesis: GlycA would associate with aortic vascular inflammation (VI), assessed as target-to-background ratio (TBR), by FDG PET/CT in PSO.
Methods: Consecutive PSO patients (n=151) underwent FDG PET/CT scans at baseline as part of a large cohort study (NCT01778569). 95 patients also underwent repeat scans at 1-year. GlycA was measured by nuclear magnetic resonance (LabCorp). Labs were measured in a certified clinical research facility. Statistical analyses included multivariable regression and ROC modeling.
Results: PSO patients were middle aged, at low Framingham risk, but had significant cardiometabolic dysfunction (Table). While hsCRP did not associate with TBR (β=0.03, p=0.7), GlycA was strongly associated with TBR beyond traditional risk factors and hsCRP in PSO (β=0.22, p<0.001). ROC demonstrated greater AUC for GlycA in predicting TBR (p<0.01), suggesting GlycA adds value in CV risk assessment. At 1-year, GlycA decreased (p<0.001) concomitant with decreased skin inflammation, whereas hsCRP reduction did not achieve significance (p=0.06). The relationship between TBR and GlycA persisted at 1-year (β=0.23, p=0.04), while hsCRP still had no association with TBR at 1-year (β=0.01, p=0.9). Finally, GlycA added value in predicting TBR even at 1-year on ROC (p=0.002).
Conclusion: GlycA associated with VI in PSO beyond hsCRP and added value in TBR prediction, at baseline and 1-year. However, we did not find similar results with hsCRP. Our findings support a potential role for GlycA, as a reliable biomarker, beyond hsCRP in CV risk assessment in PSO. Larger studies are needed to confirm our findings.
Author Disclosures: A.A. Joshi: None. J.B. Lerman: None. T.M. Aberra: None. M.T. Kabbany: None. A.K. Dey: None. A. Chaturvedi: None. H.L. Teague: None. J.I. Silverman: None. Q. Ng: None. T.Z. Aridi: None. B. Natarajan: None. M.A. Ahlman: None. J. Rodante: None. M.P. Playford: None. J. Gelfand: None. N.N. Mehta: None.
- © 2016 by American Heart Association, Inc.